FDA 483 - Qualgen LLC - September 13, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
This FDA Form 483 details numerous deficiencies at a facility manufacturing Testosterone and Estradiol pellets.
**Facility and Operations:** The firm produces Testosterone and Estradiol pellets, including Testosterone 100mg, Estradiol 6mg, Estradiol 15mg, Estradiol 10mg, Testosterone 200mg/Anastrozole 20mg. Operations involve ISO 5 hoods (Biological Safety Cabinets - BSCs), ISO 7 cleanrooms, ISO 8 Prep Room, and ISO 8 Ante Room.
**Violations and Observations:** * **Inadequate Investigations:** Failure to thoroughly investigate unexplained discrepancies, batch failures, and out-of-specification results. * Eight environmental monitoring action level excursions (April 2017-July 2018) in ISO 5 hoods (3 in Testosterone BSC, 5 in Estradiol BSC) lacked identified root causes and comprehensive reviews. * An April 23, 2018, ISO 7 surface excursion (TNTC CFUs) lacked investigation and isolate identification. * Rejected Testosterone 100mg pellets (Lot D048, Feb 2018) due to "poor quality" lacked investigation. * A May 3, 2018, gowning qualification failure lacked investigation and isolate identification. *
ID · f752d77c-34db-47e5-802a-843e3399a02f
Full citation text and observation details available on the Dashboard.